Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) --...
November 09, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem...
November 02, 2023 09:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch – –...
September 26, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
August 09, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended...
May 11, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing...
April 17, 2023 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
April 12, 2023 08:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Leadership Changes

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – –...
March 16, 2023 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected...
March 15, 2023 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the AACR Annual Meeting 2023

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...